AssetMark’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$54 Hold
1
– – ﹤0.01% 3715
2026
Q2
$42 Hold
1
– – ﹤0.01% 3506
2026
Q1
$26 Hold
1
– – ﹤0.01% 3418
2025
Q4
$29 Buy
+1
New +$30 ﹤0.01% 3351
2022
Q2
– Sell
-57
Closed -$3K – 1471
2022
Q1
$3K Buy
+57
New +$2.72K ﹤0.01% 1341
2021
Q4
– Sell
-13,397
Closed -$1M – 1505
2021
Q3
$1M Sell
13,397
-5,414
-29% -$454K ﹤0.01% 390
2021
Q2
$1.74M Buy
18,811
+3,635
+24% +$309K 0.01% 334
2021
Q1
$1.35M Buy
15,176
+1,617
+12% +$160K 0.01% 339
2020
Q4
$1.26M Buy
+13,559
New +$1.08M 0.01% 335

Other funds holding ARKG

AssetMark's ARKG Position: Q3 2026 in Review

AssetMark held its ARK Genomic Revolution ETF (ARKG) position steady in Q3 2026 at 1 share worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #3715.

AssetMark first reported a position in ARKG in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.74M in Q2 2021. 260 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

  • AssetMark held 1 share of ARK Genomic Revolution ETF worth $54 as of Q3 2026.
  • AssetMark left its ARK Genomic Revolution ETF share count unchanged in Q3 2026.
  • ARK Genomic Revolution ETF made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3715 holding.
  • AssetMark first reported a position in ARK Genomic Revolution ETF in Q4 2020 and has held it in 9 quarters since.
  • AssetMark's ARK Genomic Revolution ETF position peaked at $1.74M in Q2 2021.
  • 260 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.